Publications
663 results found
Pender A, Coward J, Gunapala R, et al., 2013, Outcomes of patients undergoing adjuvant platinum-vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC), Publisher: ELSEVIER IRELAND LTD, Pages: S12-S12, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 2
Coward JIG, Ding N-L, Feakins R, et al., 2012, Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report, MEDICAL ONCOLOGY, Vol: 29, Pages: 2623-2625, ISSN: 1357-0560
- Author Web Link
- Cite
- Citations: 3
Twelves C, Chmielowska E, Havel L, et al., 2012, RANDOMISED PHASE II STUDY OF AXITINIB OR BEVACIZUMAB COMBINED WITH PACLITAXEL/CARBOPLATIN (PAC/CARB) AS FIRST-LINE THERAPY FOR PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: OXFORD UNIV PRESS, Pages: 409-409, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 1
Papa S, Popat S, Shah R, et al., 2012, A PHASE 2 STUDY OF SORAFENIB AFTER FIRST LINE PLATINUM CONTAINING COMBINATION CHEMOTHERAPY IN MALIGNANT MESOTHELIOMA, 3rd European Lung Cancer Conference (ELCC), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S84-S84, ISSN: 1556-0864
Popat S, 2012, LARGE CELL NEUROENDOCRINE CARCINOMA: HOW SHOULD IT BE TREATED?, 3rd European Lung Cancer Conference (ELCC), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S18-S18, ISSN: 1556-0864
O'Brien M, Gaafar RM, Popat S, et al., 2012, Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052, 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Popat S, Gonzalez D, Min T, et al., 2012, <i>ALK</i> translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma, LUNG CANCER, Vol: 75, Pages: 300-305, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 41
Aleksic A, Popat S, 2012, Treatment of small cell lung cancer, Lung Cancer Therapy Annual 7, Pages: 138-149, ISBN: 9781841848655
INTRODUCTION Lung cancer is the most common cause of cancer-related deaths in Europe, accounting for 334,800 individuals dying from the disease in 2006. Small cell lung cancer (SCLC) accounts for 15-18% of prevalent cases, and is strongly associated with smoking. While increased public awareness of harmful effects of smoking has resulted in a decreased lung cancer-specifi c mortality in the Western world, and a likely future fall in incidence due to successful smoking cessation programs, smoking is an increasing problem in Asia, and will still result in a signifi cant number of patients in years to come. The SCLC incidence in the United States between 1973 and 2000 decreased due to fewer smokers and the use of low-tar fi lter cigarettes. However, only a modest improvement in survival has been observed in the last 30 years.
Nimako K, Popat S, 2012, Management of lung cancer, Medicine, Vol: 40, Pages: 202-207, ISSN: 1357-3039
Surgery, chemotherapy, radiotherapy and palliative care all have a role in the management of patients with lung cancer. Lung cancer is a heterogeneous group of diseases at both histopathological and molecular levels. Individual treatment plans should be contingent on the histological and molecular characteristics of the tumour as well as on the stage of disease at diagnosis, performance status and co-morbidities. Recent advances in the management of non-small cell lung cancer (NSCLC) have included histology-directed, molecular-directed, and maintenance therapies. There have been fewer advances in small cell lung cancer (SCLC) management and treatment outcomes have plateaued. Management decisions should be made at a multidisciplinary team (MDT) meeting, with core members including a respiratory physician, an oncologist, a thoracic surgeon, a radiologist, a pathologist, and a palliative care team member. © 2012 Elsevier Ltd. All rights reserved.
Freidin M, Nicholson A, Popat S, et al., 2012, Distribution profile of baseline gene expression to standardise tumour expression: a pilot study of cisplatin resistant genes in lung cancer, Publisher: ELSEVIER IRELAND LTD, Pages: S2-S3, ISSN: 0169-5002
Myerson J, O'Brien M, Waddell T, et al., 2012, The UK 'two week rule' for lung cancer-5-year survival update, Publisher: ELSEVIER IRELAND LTD, Pages: S25-S26, ISSN: 0169-5002
Coward JIG, Nathavitharana R, Popat S, 2012, True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer, LUNG CANCER, Vol: 75, Pages: 133-135, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 2
O'Brien MER, Myerson JS, Coward JIG, et al., 2012, A phase II study of <SUP>18</SUP>F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12 weeks, EUROPEAN JOURNAL OF CANCER, Vol: 48, Pages: 68-74, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 21
Leary AF, de Castro DG, Nicholson AG, et al., 2012, Establishing an <i>EGFR</i> mutation screening service for non-small cell lung cancer - Sample quality criteria and candidate histological predictors, EUROPEAN JOURNAL OF CANCER, Vol: 48, Pages: 61-67, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 32
Tai FWD, Khor KS, Popat S, et al., 2012, Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer, Publisher: ELSEVIER IRELAND LTD, Pages: S12-S12, ISSN: 0169-5002
Pender A, Letsa I, Reid A, et al., 2012, Weekly paclitaxel and three weekly docetaxel appear active and well-tolerated in third and fourth-line advanced NSCLC patients, Publisher: ELSEVIER IRELAND LTD, Pages: S7-S7, ISSN: 0169-5002
Popat S, de Araujo AV, Min T, et al., 2011, Lung Adenocarcinoma with Concurrent Exon 19 <i>EGFR</i> Mutation and <i>ALK</i> Rearrangement Responding to Erlotinib, JOURNAL OF THORACIC ONCOLOGY, Vol: 6, Pages: 1962-1963, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 65
Hubner RA, Riley RD, Billingham LJ, et al., 2011, Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations, PLOS ONE, Vol: 6, ISSN: 1932-6203
- Author Web Link
- Open Access Link
- Cite
- Citations: 70
Hubner RA, Goldstein R, Mitchell S, et al., 2011, Influence of co-morbidity on renal function assessment by Cockcroft-Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy, LUNG CANCER, Vol: 73, Pages: 356-360, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 6
Calderone R, Nimako K, Leary A, et al., 2011, Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease - a short communication, EUROPEAN JOURNAL OF CANCER, Vol: 47, Pages: 1603-1605, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 10
Popat S, Riley RD, Billingham LJ, et al., 2011, EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 (ERCC1) STATUS AND NON-SMALL CELL LUNG CANCER (NSCLC) OUTCOMES: A META-ANALYSIS OF PUBLISHED STUDIES AND RECOMMENDATIONS, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S438-S439, ISSN: 1556-0864
Waddell TS, Myerson J, Reid A, et al., 2011, THE UK TWO WEEK RULE INITIATIVE IN LUNG CANCER - FIRST REPORT OF IMPACT ON DISEASE STAGE AND 5-YEAR SURVIVAL, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S523-S524, ISSN: 1556-0864
Leary A, Gonzalez D, Nicholson AG, et al., 2011, SAMPLE QUALITY CRITERIA FOR ROUTINE EGFR MUTATION SCREENING - PATHOLOGICAL FEATURES MAY BE MORE USEFUL THAN CLINICAL PHENOTYPE IN A UK POPULATION, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S569-S570, ISSN: 1556-0864
Freidin MB, Bhudia N, Lim E, et al., 2011, SAMPLE HANDLING AND PROCESSING ARE CRITICAL FACTORS INFLUENCING THE RESULTS OF WHOLE GENOME GENE EXPRESSION PROFILING IN LUNG CANCER TISSUES, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S373-S374, ISSN: 1556-0864
Pattenden H, Deshmukh M, Dusmet M, et al., 2011, PERIPHERAL VERSUS CENTRAL RESECTED PRIMARY SQUAMOUS CELL CARCINOMAS OF THE LUNG - A REVIEW OF 526 CASES., Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S445-S446, ISSN: 1556-0864
Popat S, Gonzalez D, Min T, et al., 2011, ALK TRANSLOCATION IS ASSOCIATED WITH ALK IMMUNOREACTIVITY AND EXTENSIVE SIGNET-RING MORPHOLOGY IN PRIMARY LUNG ADENOCARCINOMA., Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S506-S507, ISSN: 1556-0864
Patton S, Thunnissen E, Murray S, et al., 2011, A PILOT EXTERNAL QUALITY ASSURANCE SCHEME FOR SOMATIC EGFR MUTATION TESTING IN NON-SMALL CELL LUNG CANCER, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S1510-S1511, ISSN: 1556-0864
Tai FWD, Khor KS, Popat S, et al., 2011, ONCOLOGISTS, PHYSICIANS AND SURGEONS OPINIONS ON THE PERCEIVED VALUE AND APPROPRIATENESS OF THE SPECIALITY TO INFORM PATIENTS ON ADJUVANT CHEMOTHERAPY AFTER RADICAL SURGERY FOR NON-SMALL CELL LUNG CANCER, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S1334-S1334, ISSN: 1556-0864
Reid A, Waddell TS, Nimako K, et al., 2011, WEEKLY PACLITAXEL APPEARS ACTIVE AND WELL-TOLERATED IN THIRD AND FOURTH-LINE ADVANCED NSCLC PATIENTS, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S1301-S1301, ISSN: 1556-0864
Myerson JS, Nimako K, Moore S, et al., 2011, QUALITY OF LIFE ASSESSMENTS IN LUNG CANCER AND MESOTHELIOMA. A COMPARISON OF QUESTIONNAIRES AND PHYSICIAN CONSULTATION - A POOR WORKMAN ALWAYS BLAMES HIS TOOLS?, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: S1206-S1207, ISSN: 1556-0864
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.